1. Signaling Pathways
  2. Anti-infection
  3. SARS-CoV

SARS-CoV

SARS-CoV (SARS coronavirus) is the virus that causes severe acute respiratory syndrome (SARS). Coronaviruses encode papain-like proteases (PLpro) that are often multifunctional enzymes with protease activity to process the viral replicase polyprotein and deubiquitinating (DUB)/deISGylating activity, which is hypothesized to modify the innate immune response to infection.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) is the epidemic and the challenge. COVID-19 is similar to the CoV circulating in Rhinolophus, with a 98.7% nucleotide similarity to the partial RNA dependent RNA polymerase gene of the bat coronavirus strain BtCoV/4991 and 87.9% nucleotide similarity to bat coronavirus strain bat-SL-CoVZC45 and bat-SL-CoVZXC21. Remdesivir and Chloroquine are promising agents against COVID-19.

SARS-CoV Related Products (16):

Cat. No. Product Name Effect Purity
  • HY-17589
    Chloroquine phosphate Inhibitor 99.94%
    Chloroquine phosphate is an inhibitor of autophagy and toll-like receptors (TLRs). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.
  • HY-104077
    Remdesivir Inhibitor 99.74%
    Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro.
  • HY-14768
    Favipiravir Inhibitor 98.50%
    Favipiravir (T-705) is a novel viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with IC50 of 341 nM.
  • HY-13765
    6-Thioguanine Inhibitor >98.0%
    6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC50s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.
  • HY-17470
    Mizoribine Inhibitor 99.98%
    Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC50 of approximately 100 μM for anti-HCV activity. Immunosuppressant. Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC50s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively.
  • HY-135860
    SARS-CoV-2-IN-1 Inhibitor
    SARS-CoV-2-IN-1 is a potent Mpro inhibitor. SARS-CoV-2-IN-1 inhibits the purified recombinant SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC50s of 0.67, 0.90 and 0.58 μM, respectively.
  • HY-135858
    SARS-CoV-IN-3 Inhibitor
    SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-3 shows anti-Coronavirus activity with an EC50 of 3.6 μM in Vero cells. SARS-CoV-IN-3 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 11.7 and 20.4 nM; and IC90s of 29.19 and 56 nM; respectively. SARS-CoV-IN-3 reduces HIV-1-induced cytopathic effect with an EC50 of 10 μM in MT-4 cells.
  • HY-N0752
    Scutellarein Inhibitor 99.67%
    Scutellarin, a main active ingredient extracted from Erigeron breviscapus (Vant.
  • HY-117043
    GRL0617 Inhibitor 99.78%
    GRL0617 is a potent, selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro)/deubiquitinase, with an IC50 of 0.6 μM, and with a Ki of 0.49 μM.
  • HY-N1910
    4'-O-Methylbavachalcone Inhibitor 99.64%
    4'-O-Methylbavachalcone is a chalcone isolated from Psoralea corylifolia, inhibits severe acute respiratory syndrome coronavirus (SARS-CoV) papain-like protease (PLpro) activity, with an IC50 of 10.1 μM.
  • HY-17542
    PLpro inhibitor Inhibitor 99.79%
    PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with IC50 of 2.6 uM.
  • HY-135803
    T-705RTP Inhibitor
    T-705RTP is a selective and GTP-competitive influenza virus RNA polymerase inhibitor with an IC50 of 0.14 μM and a Ki of 1.52 μM. T-705RTP is the active triphosphate metabolite of T-705 and has potent anti-influenza virus activity.
  • HY-135855
    SARS-CoV-IN-1 Inhibitor
    SARS-CoV-IN-1 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-1 shows anti-Coronavirus activity with an EC50 of 4.9 μM in Vero cells. SARS-CoV-IN-1 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 15.4 and 133.2 nM; and IC90s of 25.7 and 459.1 nM; respectively. Antimalarial and antiviral activities.
  • HY-135856
    SARS-CoV-IN-2 Inhibitor
    SARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-2 shows anti-Coronavirus activity with an EC50 of 1.9 μM in Vero cells. SARS-CoV-IN-2 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 21.5 and 30 nM; and IC90s of 51.0 and 99.9 nM; respectively. SARS-CoV-IN-2 reduces HIV-1-induced cytopathic effect with an EC50 of 2.9 μM in MT-4 cells. Antimalarial and Antiviral Activities.
  • HY-135853
    EIDD-2801 Inhibitor
    EIDD-2801 is an orally bioavailable isopropylester prodrug of the ribonucleoside analog EIDD-1931. EIDD-2801 shows anti-influenza virus and coronaviruses activities. EIDD-2801 has the potential for seasonal and pandemic influenza treatment.
  • HY-135791
    T-705RTP sodium Inhibitor
    T-705RTP sodium is a selective and GTP-competitive influenza virus RNA polymerase inhibitor with an IC50 of 0.14 μM and a Ki of 1.52 μM. T-705RTP sodium is the active triphosphate metabolite of T-705 and has potent anti-influenza virus activity.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.